



# ONCOLOGY

## SPONSORED PROFILE

Medtronic

# Performer multifunction system for the support of regional cancer therapies

Performer is an innovative, multifunctional and integrated system capable of supporting several therapies based on blood/fluids extracorporeal circulation. Performer LRT has been developed for the support of regional cancer therapies

**C**hemotherapeutic drugs are by definition toxic, and their use in high concentrations may result in serious side-effects. Regional cancer therapies allow much higher concentrations to be targeted at cancer sites, but the drugs must be prevented from dispersing beyond the immediate area of activity. Performer LRT – a safe and efficient method of enabling this – has applications in a large number of surgical procedures, including many previously untreatable cases. Circuit parameters (ie, temperature, flow and volume) can be easily and safely monitored and adjusted throughout the whole treatment. To this purpose, Performer LRT equipment provides the following devices:

- Heating system.
- Eight medical thermistor probes.
- Syringe pump.
- Four peristaltic pumps.
- Fluid balance control.
- Pressure monitoring.
- Oxygen saturation and haematocrit monitoring.
- Safety air detector and pinch valve.
- Blood leak detector.
- Buffer battery pack.
- Touchscreen, memory card and printer.

### Hyperthermic intraperitoneal perfusion

This treatment consists in the perfusion of the peritoneal cavity with chemotherapeutic drugs (normally cisplatin and mitomycin C) at a controlled temperature of 42.5°C and average flow of 800/900 ml/min for 60-90 minutes duration.

Treatment is indicated after cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis from gastrointestinal and ovarian carcinoma and abdominal sarcoma, in pseudomyxoma peritonei and in peritoneal mesothelioma.

### Isolated (limb) hyperthermic perfusion

This technique requires surgical isolation of the anatomical region, typically a limb, and hyperthermic perfusion (41.5°C) through the artery with chemotherapeutic drugs at high doses, in hyperthermia and hyperoxia/hypoxia, for 60-90 minutes. Indications are: melanoma of the limbs, primary sarcoma of the soft tissues of the limbs which cannot be radically resected and recurrent sarcoma of the soft tissues of the limbs.

### Hypoxic isolated perfusion + haemofiltration (stop flow)

Intra-arterial infusion of chemotherapeutic drugs with temporary interruption of the arterial flow (stop flow phase) of the abdominal, pelvic or thoracic regions is followed by haemofiltration. Chemotherapeutic drugs are recirculated within the isolated region in normothermic conditions for 15-20 minutes. Subsequently, a high-flow haemofiltration is performed to remove residual drug from the circulating blood.

**Indications** Pelvic region: recurrent carcinoma of the colo-rectum and/or inoperable rectal carcinoma, and sarcoma of the soft tissues, recurrent or inoperable carcinoma of the bladder, recurrent or inoperable carcinoma of the cervix and ovarian carcinoma.

Abdominal region: unresectable adenocarcinoma of the pancreas, recurrent gastric carcinoma, primary hepatic neoplasms or secondary metastasis and recurrent ovarian carcinoma after two levels of systemic chemotherapy.

Thoracic region: primary pulmonary neoplasms (excluding stage III B microcytomas), stage II and III pleural mesothelioma, unresectable pulmonary metastasis from osteosarcoma and sarcomas of the soft tissues. ■

Contact  
Andrea Menghini  
Extracorporeal Business  
Director  
Medtronic  
T: +39 0535 49307  
F: +39 0535 411665  
M: +39 335 8268944  
E: andrea.menghini@  
medtronic.com

R68

HHE 2005/2006

For information on products and services access [www.hospitalhealthcare.com](http://www.hospitalhealthcare.com)